ArticleFrontiers in neurology2025
Factors influencing health behavior changes in people with early multiple sclerosis: process evaluation of the multicenter randomized controlled POWER@MS1 trial.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Big Picture: 26 Years of Longitudinal Findings About Health Promotion and Quality of Life in Multiple Sclerosis.Healthcare (Basel, Switzerland) · 2026Review
- Effectiveness of a digital health application (Multiple sclerosis journal - experimental, translational and clinicalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Health behavior changes, i.e., optimizations of physical activity, diet, sleep and stress management, are increasingly considered as modifiers of prognostic risk in multiple sclerosis (MS). A personalized digital lifestyle management application ("levidex"), designed to support people with MS (pwMS) in coping with their diagnosis and adopting healthier behaviors, was evaluated against an active psychoeducational control program ("dexilev") in a randomized controlled trial (RCT; "POWER@MS1"). Objectives: This study evaluates the POWER@MS1 trial, focusing on the processes and organizational aspects of the study. Specifically, it seeks to (1) identify the contextual factors that influence behavior change in pwMS and (2) assess how the intervention and study design were perceived by pwMS and involved health care professionals (HCPs; neurologists, study nurses, radiologists). Methods: A mixed methods approach was applied. During the study period questionnaire data were collected from all trial participants ( Results: Quantitative trial data revealed that the levidex group significantly agreed more to behavioral changes after 3 months [levidex (6.65); dexilev (5.23), Conclusion: Health behavior change was rated as an important component of MS treatment. A digital application was perceived to be beneficial for the facilitation of relevant behavior change.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.